OverviewSuggest Edit

Ironwood Pharmaceuticals (formerly Microbia) is dedicated to creating, developing, and commercializing innovative human medicines, and has clinical-stage programs in GI disorders and dyslipidemia. The Company discovers, develops and commercializes a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also developing a pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract.

HQCambridge, MA, US
Employee Ratings4.2
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)317(-38%)
Job Openings14
Revenue (FY, 2020)$389.5 M(-9%)
Share Price (May 2021)$11.1
Cybersecurity ratingDMore

Key People/Management at Ironwood Pharmaceuticals

Mark Currie

Mark Currie

Gina Consylman

Gina Consylman

Senior Vice President, Chief Financial Officer
Marla Kessler

Marla Kessler

Andrew Dreyfus

Andrew Dreyfus

Alexander Denner

Alexander Denner

Mark Mallon

Mark Mallon

Chief Executive Officer, Director
Show more

Ironwood Pharmaceuticals Office Locations

Ironwood Pharmaceuticals has offices in Cambridge and Boston
Cambridge, MA, US (HQ)
301 Binney St
Boston, MA, US
100 Summer Street, 100 Summer St #2300
Show all (2)

Ironwood Pharmaceuticals Financials and Metrics

Ironwood Pharmaceuticals Revenue

Ironwood Pharmaceuticals's revenue was reported to be $389.52 m in FY, 2020

Revenue (Q1, 2021)


Net income (Q1, 2021)


EBIT (Q1, 2021)


Market capitalization (3-May-2021)


Closing stock price (3-May-2021)


Cash (31-Mar-2021)



Ironwood Pharmaceuticals's current market capitalization is $1.8 b.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020



Revenue growth, %


Cost of goods sold


Gross profit

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Ironwood Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Ironwood Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Ironwood Pharmaceuticals Online and Social Media Presence

Embed Graph

Ironwood Pharmaceuticals Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Ironwood Pharmaceuticals Blogs

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

– “When-issued” trading of CYCN expected to begin on Nasdaq on March 18, 2019 – – Separation completion expected April 1, 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2019-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that the Form 10 Registration Statement filed by

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the Barclays Global Healthcare Conference on Thursday, March 14, 2019 at 2:35 p.m. Eastern Time at The Loews Miami Beach Hotel in Miami .

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 39 th Annual Cowen Health Care Conference on Monday, March 11, 2019 at 4:10 p.m. Eastern Time at The Boston Marriott Copley Place in Boston .

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

– Proceeds to advance Cyclerion’s soluble guanylate cyclase (sGC) programs targeting breakthrough treatments for serious and orphan diseases – – Spin-off expected to be completed in early April 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2019-- Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 11:00 a.m. Eastern Time at the Lotte New York Palace in New York .

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

– Grew 2018 revenue 16% year-over-year to $347 million , driven primarily by U.S. LINZESS ® (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million – – Progressed separation of Ironwood and Cyclerion into two publicly-traded companies with completion expected
Show more

Ironwood Pharmaceuticals Frequently Asked Questions

  • Who are Ironwood Pharmaceuticals key executives?

    Ironwood Pharmaceuticals's key executives are Mark Currie, Gina Consylman and Marla Kessler.

  • How many employees does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 317 employees.

  • What is Ironwood Pharmaceuticals revenue?

    Latest Ironwood Pharmaceuticals annual revenue is $389.5 m.

  • What is Ironwood Pharmaceuticals revenue per employee?

    Latest Ironwood Pharmaceuticals revenue per employee is $1.2 m.

  • Who are Ironwood Pharmaceuticals competitors?

    Competitors of Ironwood Pharmaceuticals include Roivant Sciences, Cipla and EMS Pharma.

  • Where is Ironwood Pharmaceuticals headquarters?

    Ironwood Pharmaceuticals headquarters is located at 301 Binney St, Cambridge.

  • Where are Ironwood Pharmaceuticals offices?

    Ironwood Pharmaceuticals has offices in Cambridge and Boston.

  • How many offices does Ironwood Pharmaceuticals have?

    Ironwood Pharmaceuticals has 2 offices.